A detailed history of Ra Capital Management, L.P. transactions in Legend Biotech Corp stock. As of the latest transaction made, Ra Capital Management, L.P. holds 7,506,934 shares of LEGN stock, worth $325 Million. This represents 5.1% of its overall portfolio holdings.

Number of Shares
7,506,934
Previous 7,506,934 -0.0%
Holding current value
$325 Million
Previous $332 Million 10.02%
% of portfolio
5.1%
Previous 5.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$39.5 - $57.22 $297 Million - $430 Million
7,506,934 New
7,506,934 $332 Million
Q1 2024

May 15, 2024

BUY
$55.06 - $69.99 $32.8 Million - $41.7 Million
596,390 Added 9.52%
6,861,097 $385 Million
Q4 2023

Feb 14, 2024

BUY
$57.25 - $69.74 $359 Million - $437 Million
6,264,707 New
6,264,707 $377 Million
Q2 2023

Aug 14, 2023

BUY
$46.28 - $75.01 $177 Million - $287 Million
3,828,484 Added 157.15%
6,264,707 $432 Million
Q4 2022

Feb 14, 2023

BUY
$38.8 - $55.46 $3.79 Million - $5.41 Million
97,613 Added 4.17%
2,436,223 $122 Million
Q3 2022

Nov 14, 2022

BUY
$38.15 - $57.1 $89.2 Million - $134 Million
2,338,610 New
2,338,610 $95.4 Million
Q3 2021

Nov 15, 2021

SELL
$35.31 - $50.56 $34.5 Million - $49.4 Million
-977,503 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$25.8 - $41.09 $25.2 Million - $40.2 Million
977,503 New
977,503 $40.1 Million
Q1 2021

May 17, 2021

SELL
$23.55 - $32.4 $56.7 Million - $78 Million
-2,408,292 Closed
0 $0
Q3 2020

Nov 16, 2020

SELL
$27.5 - $39.61 $2.03 Million - $2.92 Million
-73,650 Reduced 2.97%
2,408,292 $74.3 Million
Q2 2020

Aug 14, 2020

BUY
$36.1 - $42.56 $89.6 Million - $106 Million
2,481,942 New
2,481,942 $106 Million

Others Institutions Holding LEGN

About Legend Biotech Corp


  • Ticker LEGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 167,403,008
  • Market Cap $7.25B
  • Description
  • Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...
More about LEGN
Track This Portfolio

Track Ra Capital Management, L.P. Portfolio

Follow Ra Capital Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ra Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Ra Capital Management, L.P. with notifications on news.